실시간

FierceBiotechCellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPO FierceBiotechBayer buys Perfuse in $2.4B deal for midphase eye disease prospect Endpoints NewsCellCentric raises $220M to get multiple myeloma pill to market FierceBiotechAfter a decade of hype, Najat Khan is bringing Recursion back down to earth Endpoints NewsBayer to buy Perfuse Therapeutics for $300M upfront FierceBiotechNovo CEO insists ‘no change in plan’ for CagriSema launch after single-chamber device ditched FierceBiotechAvalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind Endpoints NewsNovo Nordisk's Q1 in four words: Pills, pricing, payments and pressure LabiotechSickle cell disease after Casgevy: seven companies to watch in 2026 FierceBiotechJ&J’s Ottava surgical robot meets primary endpoints in gastric bypass study eLifeHER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial content eLifeCanonical neurodevelopmental trajectories of structural and functional manifolds

Labiotech 2026년 5월 6일

Sickle cell disease after Casgevy: seven companies to watch in 2026

Look into what biotech companies are developing for sickle cell disease after Casgevy's approval in 2023. The post Sickle cell disease after Casgevy: seven comp...

Look into what biotech companies are developing for sickle cell disease after Casgevy's approval in 2023. The post Sickle cell disease after Casgevy: seven companies to watch in 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.